A meta-analysis of the efficacy and safety of paclitaxel-coated balloon and ordinary balloon in the treatment of femoral popliteal arteriosclerosis obliterans

Objective To analyze the efficacy and safety of drug coated balloon in the treatment of femoral popliteal arteriosclerosis obliterans. Methods The randomized controlled trial literature on the treatment of femoral popliteal arteriosclerosis obliterans by drug coated balloon was retrieved and collected at domestic and abroad. The retrieval years were established to June 2018. Review Manager 5.1 software was used to carry out Meta analysis on the data collected and collated, compared with drug coated balloon and common balloon treatment stock. Postoperative patency and complications of popliteal arteriosclerosis obliterans. Results According to the inclusion criteria, 12 articles were included in the statistical analysis and 2 373 cases were included in the statistical analysis. The results of Meta analysis showed that the late lumen loss and restenosis at 6 months after the operation were all lower than that of the common balloon(all P<0.05). The two groups were compared with the 12-month primary patency rate, and the heterogeneity test showed significant difference(χ²=13.660, P<0.05, I²=71%). The random effect model was used to analyze the patency rate of the drug coated balloon significantly better than that of the common balloon(P<0.05). The longest follow-up to 12 months after the operation was compared with the rate of amputation, and there was no significant difference in the heterogeneity test(χ²=0.420, P=0.510, I²=0%). The amputation rate of two groups was not significantly different(P=0.710). After follow up to 24 months, the drug coated balloon was significantly better than that of the common balloon(P<0.05). Conclusion The drug coated balloon in the treatment of femoral popliteal arteriosclerosis obliterans has better clinical advantages than common balloon, which can help to reduce the incidence of restenosis and restenosis after operation, and improve the long-term patency rate.